NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Teleflex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its officers/directors, following a significant stock price drop after FDA news regarding its drug application [1][4]. Group 1: FDA Announcement and Stock Impact - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, a treatment for recurrent respiratory papillomatosis, but did not find sufficient information for accelerated approval [3]. - Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Inovio regarding claims of potential securities fraud and is encouraging them to contact the firm for further information [1].

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apogee Enterprises, Inc. (“Apogee” or the “Company”) (NASDAQ: APOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Apogee and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January ...

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. regarding allegations of securities fraud and unlawful business practices following a significant drop in share price after its IPO [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Fermi and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until March 6, 2026, to request to be appointed as Lead Plaintiff if they purchased Fermi securities related to its IPO [2]. Group 2: IPO and Subsequent Developments - Fermi completed its IPO on October 1, 2025, offering 32.5 million shares at a price of $21.00 per share [4]. - On December 12, 2025, Fermi announced the termination of a $150 million Advance in Aid of Construction Agreement for its Project Matador data center, which negatively impacted investor confidence and share price [4].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations against Alexandria and certain officers and/or directors regarding securities fraud [2]. - Investors have until January 26, 2026, to request to be appointed as Lead Plaintiff if they purchased Alexandria securities during the Class Period [2]. Group 2: Financial Performance - On October 27, 2025, Alexandria reported disappointing financial results for Q3 2025, including a reduction in full-year 2025 funds from operations (FFO) guidance [4]. - The company cited lower occupancy rates, slower leasing activity, and a significant real estate impairment charge of $323.9 million, with $206 million related to its Long Island City property [4]. Group 3: Market Reaction - Following the announcement of the financial results, Alexandria's stock price dropped by $14.93 per share, or 19.17%, closing at $62.94 per share on October 28, 2025 [5].

Group 1 - Fortress Biotech Inc. is under investigation by Pomerantz LLP for potential securities fraud or unlawful business practices involving its officers and/or directors [1] - On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, received a Complete Response Letter (CRL) from the U.S. FDA regarding the New Drug Application for CUTX-101, citing cGMP deficiencies at the manufacturing facility [1] - Following the announcement of the CRL, Fortress's stock price dropped by $1.14 per share, representing a decline of 30.81%, closing at $2.56 per share on the same day [1] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has a legacy of recovering multimillion-dollar damages awards for class members over its 85 years of operation [2]

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth prospects during the specified Class Period from December 12, 2024, to June 30, 2025 [1][4]. Company Overview - Centene Corporation is a healthcare enterprise that provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals [3]. Allegations and Misleading Information - The lawsuit claims that Centene's management misled investors by presenting a false impression of reliable information concerning the company's projected revenue and growth, emphasizing strong enrollment rates and low morbidity levels [4]. - Contrary to these claims, the complaint alleges that there were adverse enrollment trends and worsening morbidity rates that were concealed from investors [5]. Financial Impact and Guidance Revision - On July 1, 2025, Centene withdrew its 2025 guidance, revealing disappointing findings from an internal analysis that indicated market growth across 22 states, which account for approximately 72% of its marketplace membership, was significantly below expectations [6]. - Following this announcement, Centene revised its earnings guidance downward to approximately $1.8 billion, translating to an adjusted diluted EPS of $2.75 [6]. - The stock price of Centene dropped by more than 40% after the guidance revision, resulting in substantial financial harm to investors [7].

Core Viewpoint - CPI Card Group Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - On August 8, 2025, CPI reported Q2 2025 financial results that missed both revenue and earnings estimates, with a GAAP earnings-per-share of $0.04, falling short by $0.46, and revenue of $129.75 million, missing estimates by $3.21 million [3]. - The company revised its 2025 outlook, now expecting net sales growth in the low double-digit to mid-teens range, an increase from the previous mid-to-high single-digit growth forecast [3]. Stock Market Reaction - Following the announcement of the financial results, CPI's stock price dropped by $5.37 per share, or 28.83%, closing at $13.25 per share on August 8, 2025 [4]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of CPI investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Sensus Healthcare, Inc. and its officers or directors [1] Financial Performance - On August 7, 2025, Sensus reported a second quarter GAAP earnings-per-share of -$0.06, missing estimates by $0.09 [3] - The company's revenue for the second quarter was $7.3 million, reflecting a year-over-year decline of 20.7% and missing estimates by $2 million [3] - The revenue decline was primarily attributed to a lower number of units sold to a large customer, although there was some offset from growth in recurring revenue from Fair Deal Agreements [3] Stock Market Reaction - Following the financial results announcement, Sensus's stock price dropped by $1.89 per share, or 35.32%, closing at $3.46 per share on August 8, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Nutex Health Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation and Allegations - The investigation by Pomerantz LLP is focused on whether Nutex and its executives have engaged in securities fraud or other unlawful business practices [1]. - Blue Orca Capital issued a short report alleging that Nutex faces litigation risk due to its relationship with HaloMD, which has been sued for a fraudulent scheme involving insurance companies [3]. Group 2: Market Reaction - Following the publication of the Blue Orca report, Nutex's stock price fell by $11.18 per share, representing a decline of 10.05%, closing at $100.01 per share on July 22, 2025 [4].